UroGen Pharma (URGN) Non-Current Debt (2022 - 2026)
UroGen Pharma's (URGN) quarterly Non-Current Debt came in at $189.5 million in Q1 2026, up 55.22% YoY from $122.1 million in Q1 2025, and up 55.09% on a QoQ basis from $122.2 million in Q4 2025.
UroGen Pharma (URGN) Non-Current Debt (2022 - 2026) Analysis & Trends
UroGen Pharma (URGN) has 5 years of Non-Current Debt data on file, last reported at $189.5 million in Q1 2026.
- Quarterly Non-Current Debt rose 55.22% year-over-year to $189.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $189.5 million (up 55.22% YoY) and the FY2025 annual result came in at $122.2 million, changed 0.39% from the prior year.
- Non-Current Debt rose to $189.5 million in Q1 2026, from $122.2 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $189.5 million in Q1 2026 to a low of $70.8 million in Q1 2022.
- A 5-year average of $107.2 million and a median of $98.5 million in 2023 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2024 — Non-Current Debt slipped 0.49% — and 2026, when it surged 55.22%.
- Tracing URGN's Non-Current Debt over 5 years: stood at $97.5 million in 2022, then grew by 1.04% to $98.6 million in 2023, then gained by 23.52% to $121.7 million in 2024, then rose by 0.39% to $122.2 million in 2025, then surged by 55.09% to $189.5 million in 2026.
- The last three Non-Current Debt figures came in at $189.5 million (Q1 2026), $122.2 million (Q4 2025), and $122.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | UroGen Pharma | 2.36 Bn | 2.25 Bn | 65.88 Mn | 188.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 188.73 Mn |
| Mar 31, 2026 | 189.53 Mn |
| Dec 31, 2025 | 122.21 Mn |
| Sep 30, 2025 | 122.11 Mn |
| Jun 30, 2025 | 122.51 Mn |
| Mar 31, 2025 | 122.11 Mn |
| Dec 31, 2024 | 121.73 Mn |
| Sep 30, 2024 | 121.71 Mn |
| Jun 30, 2024 | 97.81 Mn |
| Mar 31, 2024 | 97.59 Mn |
| Dec 31, 2023 | 98.55 Mn |
| Sep 30, 2023 | 98.52 Mn |
| Jun 30, 2023 | 98.30 Mn |
| Mar 31, 2023 | 97.94 Mn |
| Dec 31, 2022 | 97.54 Mn |
| Sep 30, 2022 | 71.87 Mn |
| Jun 30, 2022 | 71.20 Mn |
| Mar 31, 2022 | 70.80 Mn |